A.S. Narain Naidu, PhD (Medicine), FACN, FLS is a medical microbiologist / immunologist with over 35 years of research expertise on bioactive molecules and their benefits to human health. Since receiving his Doctorate in 1985, Dr. Naidu has served the Directorate of Public Health Services for the Government of India, the World Health Organization, the Biomedical Center-Uppsala, Malmo General Hospital-Sweden, and UNC-Chapel Hill. His ground-breaking discoveries of Staphylococcal toxic shock syndrome and E.coli hemolytic syndrome have brought him international recognition. Dr. Naidu has been a principal investigator for several NIH grants, published more than 100 peer-reviewed research papers, written over 30 book chapters and authored 4 scientific reference volumes: REDOX Life, Bio-Replenishment for Bone Health, Food Antimicrobial Systems and Lactoferrin. He is an associate of 18 International Scientific Societies. Dr. Naidu’s discoveries and inventions are the basis for founding of 5 successful biotechnology companies. Dr. Naidu’s expertise includes epidemiological surveillances, differential diagnosis and intervention of emerging infections and intoxicatons; developing globalhealth projects; designing clinical trials; guide-supervision of research groups; exploring intellectual properties and strategic technology transfers. He holds numerous core patents and his health technologies reach across 5 continents.
• 2009 – Global launch of CalDenx®, a calcium supplement synergistic to OsteoDenx® that promotes both trans- and para-cellular calcium absorption in the gastrointestinal tract.
• 2008 – Global launch of OsteoDenx® bone-replenishment technology to optimize bone turnover/bone inflammatory responses. Efficacy of the patented syno-Portin® target delivery system has been proven in 2 clinical trials.
• 2004 – Global launch of Lactoferrin Gold 1.8® technology. Introduction of a novel 3-tier process for enhanced performance of lactoferrin in the gastrointestinal tract. Over 60 million doses were distributed in 36 countries.
• 2003 – Development of ‘MILLERIN’, a broad-spectrum anti-fungal system for clinical management of vulvo-vaginal candidiasis that controls Candida albicans and Candida glabrata.
• 2002 – Technology transfer of ‘Microbial Blocking Agents’ for use in dentifrices, surgical sutures and skin cremes.
• 2001 – Introduction (North America) of ‘activated lactoferrin (ALF)’ technology for food safety. This new class of microbial blocking agents have a wide spectrum of application in beef, poultry and other meat processing industries for protection against E.coli O157:H7, Salmonella and other food-borne pathogens.
• 1999 – Introduction (USA and Japan) of probiotic ‘KE-99’ technology in human and veterinary health markets.
Technology (IP) development:
• Evaluating the prophylactic and therapeutic role of natural compounds (i.e. lactoferrin, milk components). Comprising studies on host-parasite interactions and testing evaluating Microbio-stasis, Microbio-cidal, Opsonic, and antiadhesive properties of substances.
• Evaluating the prophylactic and therapeutic role of probiotics in human and animal health.
• Screening immunomodulatory properties of natural substances such as colicins, toxins, milk components.
• Screening subepithelial matrix proteins (fibronectin, fibrinogen, various types of collagens, laminin, vitronectin, etc), and receptor analogs in prevention of bacterial adhesion to tissues. Also developed a GRP-based compound for specific inhibition of streptococcal adhesion to pharyngeal epithelial cells.
• Evaluating the antibiotic potentiation effects of lactoferrin and the kinetics of antibiotic penetration via porin channels in bacterial outer membranes.
• Developing simple rapid diagnostic assays. The PAA (Particle Agglutination Assay) test for rapid detection of bacterial receptors of molecular adhesion; The ELBA (Enzyme-linked Ligand Binding Assay) test for rapid detection of ligand interactions with microbial surfaces.